Theratechnologies organizacji ROCE
Jaka jest wartość ROCE organizacji Theratechnologies?
Wartość ROCE organizacji Theratechnologies, Inc. to 0.00%
Jaka jest definicja ROCE?
Zwrot z zaangażowanego kapitału Return on capital employed (ROCE) to wskaźnik finansowy, który mierzy zyskowność przedsiębiorstwa i efektywność, z jaką wykorzystywany jest jego kapitał.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE firm w Health Care sektor na TSX w porównaniu do Theratechnologies
Czym się zajmuję organizacja Theratechnologies?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Firmy z roce podobne do Theratechnologies
- Wartość ROCE organizacji Omega Alpha Spac to -0.01%
- Wartość ROCE organizacji The Gap to -0.01%
- Wartość ROCE organizacji Elemental Royalties Ltd to -0.01%
- Wartość ROCE organizacji Auburn National Bancorp to -0.01%
- Wartość ROCE organizacji Galaxy Digital to -0.01%
- Wartość ROCE organizacji The Gap to -0.01%
- Wartość ROCE organizacji Theratechnologies to 0.00%
- Wartość ROCE organizacji Tejon Ranch Co to 0.01%
- Wartość ROCE organizacji Glen Burnie Bancorp to 0.02%
- Wartość ROCE organizacji MSP Steel & Power to 0.02%
- Wartość ROCE organizacji TTL Beteiligungs- und Grundbesitz-AG to 0.03%
- Wartość ROCE organizacji First Foundation Inc to 0.03%
- Wartość ROCE organizacji FirstMark Horizon Acquisition to 0.03%